Episurf Medical Q4: Comments on the report - Redeye

Redeye provides its initial comments on the report ahead of a more detailed update discussing the case as we advance into 2022. Our Q4’21 estimates were off, but we emphasize the early stage for Episurf and that its current activities are well underway to build a strong fundament for long-term growth. We will, however, make downwards adjustments to our estimates, but with no particular impact on our Base Case at SEK 5 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/832692/episurf-medical-q4-comments-on-the-report?utm_source=finwire&utm_medium=RSS